CN109985002A - A kind of flurbiprofen axetil Fat Emulsion and preparation method thereof - Google Patents
A kind of flurbiprofen axetil Fat Emulsion and preparation method thereof Download PDFInfo
- Publication number
- CN109985002A CN109985002A CN201711482173.1A CN201711482173A CN109985002A CN 109985002 A CN109985002 A CN 109985002A CN 201711482173 A CN201711482173 A CN 201711482173A CN 109985002 A CN109985002 A CN 109985002A
- Authority
- CN
- China
- Prior art keywords
- phosphatidylinositols
- fat emulsion
- flurbiprofen axetil
- phosphatidyl choline
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of flurbiprofen axetil Fat Emulsions and preparation method thereof.Wherein, which contains the phosphatide containing phosphatidyl choline and phosphatidylinositols, and it is 1wt% ~ 10wt% that wherein phosphatidylinositols, which accounts for the weight percent of phosphatide,.It applies the technical scheme of the present invention, lysophosphatidyl choline content in flurbiprofen axetil cream injecting is reduced by limiting the content of phosphatidylinositols in phosphatide to reach, to obtain a kind of lower flurbiprofen axetil Fat Emulsion of lysophosphatidyl choline content of high security, and the average grain diameter of the flurbiprofen axetil Fat Emulsion is stablized, and PFAT5 is lower.
Description
Technical field
The present invention relates to field of medicaments, in particular to a kind of flurbiprofen axetil Fat Emulsion and preparation method thereof.
Background technique
Flurbiprofen is a kind of non-steroid anti-inflammatory drug, and mechanism of action mainly inhibits arachidonic acid to cascade waterfall middle ring
The activity of oxygenase plays analgesic effect to inhibit the synthesis for causing the prostaglandin of pain and inflammatory reaction.Flurbiprofen
Ester is the prodrug of Flurbiprofen, not soluble in water.Presently commercially available product is that flurbiprofen axetil is prepared into fat emulsion injection, can
For after performing the operation and the analgesia of various cancers.
Flurbiprofen axetil Fat Emulsion (trade name Furbiprofen axetil) is according to the exploitation of drug delivery system conceptual approach with Fat Emulsion
For pharmaceutical carrier, the preparation of flurbiprofen axetil is encapsulated, irritation is small when injection, and analgesic effect is rapid-action.Flurbiprofen axetil
, mainly there are following several respects: 1) targeting in the advantages of lipid microsphere injection, and the drug of package is made to assemble enhancing medicine in lesions position
Effect；2) release for controlling packaging medicine, extends duration of efficacy；3) it is easy to transmembrane transport, promotes the absorption of drug, into one
Step shortens onset time；4) it can be injected intravenously, avoid the oral damage to alimentary canal mucous membrane；5) it is used for Postoperative Analgesia After, is not had
Central inhibitory action does not influence the revival in narcosis patient, can use immediately after surgery.
Current existing florfenicol residues are Fat Emulsion Injection, and Fat Emulsion needs to use phosphorus during the preparation process
Rouge is as emulsifier.Lysophosphatidyl choline is the main degradation products of phosphatide, is a kind of substance with stronger surface-active,
It can cause various biological effect, such as can induce cell shape and change, promote cell fusion, cause haemolysis and change Premeabilisation of cells
Property etc..Since flurbiprofen axetil Fat Emulsion is emulsion used for intravenous injection, the raising of lysophosphatidyl choline probably be will cause
Security risk.Therefore, the preparation containing phospholipid needs the content of strict control lysophosphatidyl choline.
Since Fat Emulsion is a kind of thermodynamic unstable system, the process of preparation is also more complicated, flurbiprofen axetil rouge
Fat emulsion in high-temperature sterilization or placement process it is possible that partial size is unstable or even demulsifying phenomenon, meanwhile, main ingredient fluorine
It is ester type compound than ibuprofen ester, facile hydrolysis generates impurity Flurbiprofen during storage.It is directed to flurbiprofen axetil system at present
The research of agent is the research for its average grain diameter and hydrolysis impurity stability.It there is no in the prior art and compare Lip river for fluorine
The correlative study of lysophosphatidyl choline content in fragrant ester formulation.The prior art, which there is no, provides a kind of scheme to obtain lysophosphatide
The lower flurbiprofen axetil Fat Emulsion of phatidylcholine content.
Summary of the invention
The present invention is intended to provide a kind of flurbiprofen axetil Fat Emulsion and preparation method thereof, is contained with obtaining lysophosphatidyl choline
Measure lower flurbiprofen axetil Fat Emulsion.
To achieve the goals above, according to an aspect of the invention, there is provided a kind of flurbiprofen axetil Fat Emulsion.The fluorine
Contain the phosphatide containing phosphatidyl choline and phosphatidylinositols than ibuprofen ester Fat Emulsion, wherein phosphatidylinositols accounts for the weight hundred of phosphatide
Divide than being 1wt%~10wt%.
Further, phosphatidylinositols accounts for 1wt%~8wt% of phosphatide.
Further, phosphatidylinositols accounts for 1wt%~5wt% of phosphatide.
Further, the weight percent that phosphatidylinositols accounts for phosphatide is greater than 1wt% and is less than 5wt%；Preferably, phosphorus
The weight percent that acyl inositol accounts for phosphatide is greater than 1wt% and is less than or equal to 3wt%.
Further, phosphatidyl choline be selected from natural phosphatidyl choline and its salt or synthesis phosphatidyl choline and
One of its salt is a variety of；Preferably, natural phosphatidyl choline and its salt are the phosphatide extracted in soybean or yolk
Phatidylcholine and its salt；Preferably, the phosphatidyl choline and its salt of synthesis include distearoyl phosphatidylcholine, dioleoyl phosphorus
Phosphatidylcholine, Dioctonoyl pnosphotidyl choline, L-Dimyristoylphosphatidylcholine, Dinonyl Phosphatidylcholine DDPC,
Dilauroyl Phosphatidylcholine, two mustard phosphatidyl cholines, 1- stearyl -2- oleolyl phosphatidyl choline, 1- palm
Acyl group -2- oleolyl phosphatidyl choline, 1- myristoyl -2- oleolyl phosphatidyl choline, 1- stearyl -2- palmityl
Phosphatidyl choline, 1- stearyl -2- myristoyl phosphatidyl choline, 1- palmityl -2- stearoyl phosphatidyl choline,
1- palmityl -2- myristoyl phosphatidyl choline, 1- myristoyl -2- stearoyl phosphatidyl choline and 1- nutmeg
Acyl group -2- palmityl phosphatidyl choline.
Further, phosphatidylinositols be selected from natural phosphatidylinositols and its salt or synthesis phosphatidylinositols and
One of its salt is a variety of；Preferably, natural phosphatidylinositols and its salt are the phosphatide extracted in soybean or yolk
Acyl inositol and its salt；Preferably, the phosphatidylinositols and its salt of synthesis include distearyl acyl group phosphatidylinositols, dioleoyl phosphorus
Acyl inositol, two palmityl phosphatidylinositols, two myristoyl phosphatidylinositols, 1- palmityl -2- oleolyl phosphatidyl
Acyl inositol, two pure and mild osmanthus in the February acyl phosphatidylinositols of mustard acyl phosphatidyl-4.
Further, oil for injection is selected from refined soybean oil, safflower oil, cottonseed oil, olive oil, coconut oil, castor oil, fish
Oil, medium chain mono, medium chain triglyceride dibasic acid esters, medium chain triglyceride, ethyl oleate, acetylated monoglyceride, propylene glycol dibasic acid esters,
One of group of glyceryl linoleate and polyethylene glycol glyceryl laurate ester composition is a variety of.
Further, oil for injection includes the olive oil and medium chain triglyceride that weight ratio is 1:1.
Further, flurbiprofen axetil Fat Emulsion further includes pH adjusting agent, and pH adjusting agent is selected from sodium hydroxide, hydrochloric acid, phosphorus
One of group of acid, phosphate, citric acid, citrate, acetic acid and acetate composition is a variety of.
Further, flurbiprofen axetil Fat Emulsion further includes isotonic regulator, isotonic regulator be selected from glycerol, glucose,
One of group of mannitol and propylene glycol composition is a variety of.
According to another aspect of the present invention, a kind of preparation method of any of the above-described kind of flurbiprofen axetil Fat Emulsion is provided.
The preparation method is the following steps are included: the 1) preparation of oily phase: phosphatidyl choline, phosphatidyl-4 is added into oil for injection respectively
Alcohol, flurbiprofen axetil, stir to dissolve, as oily phase；2) preparation of water phase: isotonic regulator is added in water for injection,
Stirring obtains water phase to dissolving；3) preparation of colostrum: oil made from step 1) is added in water phase made from step 2), high
Speed shearing dispersion, forms colostrum；4) high-pressure homogenising: regulating step 3) made from colostrum pH, it is high-pressure homogenising, obtain smart cream；5) it fills
Envelope sterilizes to get flurbiprofen axetil Fat Emulsion.
The content of each ingredient is 0.1~5%w/v of flurbiprofen axetil in the flurbiprofen axetil Fat Emulsion of the application, phosphatide
0.3~4%w/v, the water for injection of oil for injection 5-30%w/v and surplus.Preferably, 0.1~10%w/ of flurbiprofen axetil
V, phosphatidase 0 .6~2%w/v, oil for injection 10-30%w/v.
It applies the technical scheme of the present invention, reaches reduction Flurbiprofen by limiting the content of phosphatidylinositols in phosphatide
Lysophosphatidyl choline content in ester cream injecting, to obtain a kind of lower fluorine of lysophosphatidyl choline content of high security
Than ibuprofen ester Fat Emulsion, and the average grain diameter of the flurbiprofen axetil Fat Emulsion is stablized, and PFAT5 is also preferable.
Specific embodiment
It should be noted that in the absence of conflict, the features in the embodiments and the embodiments of the present application can phase
Mutually combination.Below in conjunction with embodiment, the present invention will be described in detail.
Fat Emulsion is a kind of thermodynamic unstable system, and flurbiprofen axetil fat emulsion is in high-temperature sterilization or placement process
In it is possible that partial size is unstable or even demulsifying phenomenon, meanwhile, main ingredient flurbiprofen axetil is ester type compound, is being stored
Facile hydrolysis generates impurity Flurbiprofen in journey.The prior art there is no a kind of scheme is provided obtain lysophosphatidyl choline content compared with
Low flurbiprofen axetil Fat Emulsion.
For above-mentioned technical problem of the existing technology, the present inventor has been surprisingly found that under study for action, Ke Yitong
The content for crossing phosphatidylinositols in restriction phosphatide reduces lysophosphatidyl choline content in flurbiprofen axetil cream injecting to reach, from
And the lower flurbiprofen axetil Fat Emulsion of lysophosphatidyl choline content for obtaining a kind of high security, and the flurbiprofen axetil
The average grain diameter of Fat Emulsion is stablized, and PFAT5 is also preferable.
A kind of typical embodiment according to the present invention provides a kind of flurbiprofen axetil Fat Emulsion.The flurbiprofen axetil rouge
Fat cream contains the phosphatide containing phosphatidyl choline and phosphatidylinositols, and wherein phosphatidylinositols accounts for phosphatidase 1 wt%~10wt%.The fluorine
It is more lower than ibuprofen ester Fat Emulsion lysophosphatidyl choline content, it is highly-safe, and the partial size of the flurbiprofen axetil Fat Emulsion point
Cloth is also preferable, can be used as a kind of good injection use.Preferably, phosphatidylinositols accounts for 1wt%~8wt% of phosphatide.
A kind of typical embodiment according to the present invention, phosphatidylinositols account for phosphatide weight percent be 1wt%~
5wt%, preferably greater than 1wt% and be less than 5wt%, further preferably greater than 1wt% and be less than or equal to 3wt%.?
In this proportional region, obtained flurbiprofen axetil Fat Emulsion is had excellent performance, especially lysophosphatidyl choline content control and
In terms of PFAT5.
A kind of typical embodiment according to the present invention, phosphatidyl choline are selected from natural phosphatidyl choline and its salt
Or one of the phosphatidyl choline synthesized and its salt or a variety of；Preferably, natural phosphatidyl choline and its salt are big
The phosphatidyl choline and its salt extracted in beans or yolk；Preferably, the phosphatidyl choline and its salt of synthesis include distearyl acyl group
Phosphatidyl choline, dioleyl phosphatidyl choline, Dioctonoyl pnosphotidyl choline, L-Dimyristoylphosphatidylcholine, two
Capryl phosphatidyl choline DDPC, Dilauroyl Phosphatidylcholine, two mustard phosphatidyl cholines, 1- stearyl -2- oil
Phosphatidyl choline, 1- palmityl -2- oleolyl phosphatidyl choline, 1- myristoyl -2- oleolyl phosphatidyl choline,
1- stearyl -2- palmityl phosphatidyl choline, 1- stearyl -2- myristoyl phosphatidyl choline, 1- palmityl -
2- stearoyl phosphatidyl choline, 1- palmityl -2- myristoyl phosphatidyl choline, 1- myristoyl -2- stearoyl
Base phosphatidyl choline and 1- myristoyl -2- palmityl phosphatidyl choline.
A kind of typical embodiment according to the present invention, phosphatidylinositols are selected from natural phosphatidylinositols and its salt
Or one of the phosphatidylinositols synthesized and its salt or a variety of；Preferably, natural phosphatidylinositols and its salt are big
The phosphatidylinositols and its salt extracted in beans or yolk；Preferably, the phosphatidylinositols and its salt of synthesis include distearyl acyl group
Phosphatidylinositols, dioleoyl phosphatidylinositols, two palmityl phosphatidylinositols, two myristoyl phosphatidylinositols, 1-
Palmityl -2- oleolyl phosphatidyl inositol, two pure and mild osmanthus in the February acyl phosphatidylinositols of mustard acyl phosphatidyl-4.
A kind of typical embodiment according to the present invention, oil for injection are selected from refined soybean oil, safflower oil, cottonseed oil, olive
Olive oil, coconut oil, castor oil, fish oil, medium chain mono, medium chain triglyceride dibasic acid esters, medium chain triglyceride, ethyl oleate, acetyl
Change one of group of monoglyceride, propylene glycol dibasic acid esters, glyceryl linoleate and polyethylene glycol glyceryl laurate ester composition or more
Kind.Preferably, oil for injection includes the olive oil and medium chain triglyceride that weight ratio is 1:1.
A kind of typical embodiment according to the present invention, flurbiprofen axetil Fat Emulsion further include pH adjusting agent, pH adjusting agent
One of group selected from sodium hydroxide, hydrochloric acid, phosphoric acid, phosphate, citric acid, citrate, acetic acid and acetate composition or
It is a variety of.
A kind of typical embodiment, flurbiprofen axetil Fat Emulsion further include isotonic regulator according to the present invention, isotonic tune
It saves agent and is selected from one of group of glycerol, glucose, mannitol and propylene glycol composition or a variety of.
A kind of typical embodiment according to the present invention provides a kind of preparation method of flurbiprofen axetil Fat Emulsion.It is somebody's turn to do
To the following steps are included: the 1) preparation of oily phase: phosphatidyl choline, phosphatidylinositols, fluorine being added into oil for injection respectively and compares Lip river
Fragrant ester, stirs to dissolve, as oily phase；2) preparation of water phase: isotonic regulator is added in water for injection, is stirred to molten
Solution, obtains water phase；3) preparation of colostrum: oil made from step 1) is added in water phase made from step 2), high speed shear point
It dissipates, forms colostrum；4) high-pressure homogenising: regulating step 3) made from colostrum pH, it is high-pressure homogenising, obtain smart cream；5) encapsulating, sterilizing,
Up to flurbiprofen axetil Fat Emulsion.
Beneficial effects of the present invention are further illustrated below in conjunction with embodiment.
Comparative example 1
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil is taken, is heated to 65 DEG C, phosphatidyl choline, phosphatidyl-ethanolamine, phosphatidyl glycerol and fluorine is added and compares Lip river
Fragrant ester, stirring and dissolving, as oily phase；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Comparative example 2
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil is taken, is heated to 65 DEG C, phosphatidyl choline, phosphatidyl-ethanolamine and flurbiprofen axetil is added, is stirred molten
Solution, as oily phase；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Comparative example 3
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil is taken, is heated to 65 DEG C, phosphatidyl choline, the pure and mild flurbiprofen axetil of phosphatidyl-4 is added, is stirred molten
Solution, as oily phase；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Comparative example 4
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil is taken, is heated to 65 DEG C, is added phosphatidyl choline, oleic acid and flurbiprofen axetil, stirring and dissolving, as
Oily phase；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Comparative example 5
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil is taken, is heated to 65 DEG C, phosphatidyl choline, phosphatidyl glycerol and flurbiprofen axetil is added, is stirred molten
Solution, as oily phase；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Embodiment 1
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil is taken, is heated to 65 DEG C, phosphatidyl choline, the pure and mild flurbiprofen axetil of phosphatidyl-4 is added, is stirred molten
Solution, as oily phase；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Embodiment 2
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil is taken, is heated to 65 DEG C, phosphatidyl choline, the pure and mild flurbiprofen axetil of phosphatidyl-4 is added, is stirred molten
Solution, as oily phase；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Embodiment 3
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil is taken, is heated to 65 DEG C, phosphatidyl choline, the pure and mild flurbiprofen axetil of phosphatidyl-4 is added, is stirred molten
Solution, as oily phase；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Embodiment 4
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil is taken, is heated to 65 DEG C, phosphatidyl choline, the pure and mild flurbiprofen axetil of phosphatidyl-4 is added, is stirred molten
Solution, as oily phase；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Embodiment 5
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil is taken, is heated to 65 DEG C, phosphatidyl choline, the pure and mild flurbiprofen axetil of phosphatidyl-4 is added, is stirred molten
Solution, as oily phase；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Embodiment 6
The component and dosage of flurbiprofen axetil Fat Emulsion, which are specifically shown in, see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil is taken, is heated to 65 DEG C, phosphatidyl choline, the pure and mild flurbiprofen axetil of phosphatidyl-4 is added, is stirred molten
Solution, as oily phase；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
The detection of 1 lysophosphatidyl choline of test case
0 under the conditions of the sample of Examples 1 to 6 and comparative example 1~2 and comparative example 4~5 is respectively placed in 60 DEG C
It, under the conditions of 10 days, 30 days, measures the content of lysophosphatidyl choline in product.
Detection method
Precision measures this product 1ml, sets in 10ml measuring bottle, adds isopropanol-normal heptane (2:1) to be diluted to scale, shake up, as
Test solution.
Separately take lysophosphatidyl choline reference substance appropriate, it is accurately weighed, add chloroform-methanol (2:1) to dissolve and quantify
The solution containing 50 μ g of lysophosphatidyl choline, 100 μ g, 200 μ g, 300 μ g, 400 μ g is made in every 1ml in dilution, as reference substance
Solution.According to following chromatographic conditions, 20 μ L of contrast solution is taken to inject liquid chromatograph, with the logarithm of reference substance solution concentration with
The logarithm of corresponding peak area calculates regression equation.
20 μ L of test solution is taken to inject liquid chromatograph, with the content of regression equation calculation lysophosphatidyl choline.
Chromatographic condition: being filler (250mm × 4.6mm, 5 μm) with silica gel；With methanol-water-glacial acetic acid-triethylamine (85:
15:0.45:0.05, v/v) it is mobile phase A, with n-hexane-isopropanol-mobile phase A (20:48:32, v/v) for Mobile phase B；Stream
Speed is 1.0ml per minute；According to the form below carries out gradient elution.40 DEG C of column temperature, detector is evaporative light scattering detector, is specifically shown in down
Table.
Test result is as shown in the table:
According to above-mentioned experimental result it can be found that flurbiprofen axetil Fat Emulsion is in shadow prepared by the embodiment of the present invention 1~6
It rings in factorial experiments, the content increasing degree of lysophosphatidyl choline is smaller, still is able to when storing 30 days under the conditions of 60 DEG C
Lower than 1.0mg/ml, and the flurbiprofen axetil Fat Emulsion of comparative example 1~2 and comparative example 4-5, lysophosphatidyl choline was at 10 days
When already exceed 1.2mg/ml.It can be seen that flurbiprofen axetil Fat Emulsion prepared by the present invention is relative to prior technique
The flurbiprofen axetil Fat Emulsion of preparation has lower lysophosphatidyl ethanolamine concentration, has higher safety.
Test case 2
0 day under the conditions of the sample of Examples 1 to 6 is respectively placed in 60 DEG C, 5 days, 10 days measurement milk particle partial sizes, partial size point
The content of cloth (should be less than 0.2) and hydrolysis impurity Flurbiprofen.Test result is as shown in the table:
According to aforementioned stable testing result it can be found that flurbiprofen axetil prepared by the embodiment of the present invention 1~6 is fatty
Newborn average grain diameter is able to maintain stabilization under the conditions of influence factor, and the content of hydrolysis impurity Flurbiprofen is relatively low.Thus
As it can be seen that phosphatidyl choline and phosphatidylinositol content can get a kind of average grain diameter and effective component within the scope of the present invention
The good flurbiprofen axetil Fat Emulsion of stability.
The detection of 3 PFAT5 of test case
The embodiment after 10 days under the conditions of 60 DEG C is measured in test case 2 according to the second method of United States Pharmacopeia USP729 (light blockage method)
The sample bulky grain PFAT5 volume content (should be less than 0.05%) of 1-6 and comparative example 3.
| Sample | PFAT5 |
| Embodiment 1 | 0.023% |
| Embodiment 2 | 0.009% |
| Embodiment 3 | 0.012% |
| Embodiment 4 | 0.037% |
| Embodiment 5 | 0.040% |
| Embodiment 6 | 0.042% |
| Comparative example 3 | 0.056% |
According to above-mentioned test result it can be found that the PFAT5 of the embodiment of the present application 1-6 can be protected in influence factor test
It is fixed to keep steady, and is being greater than 1wt% and is being less than or equal to be in reduced levels within the scope of 3wt%, when phosphatidylinositols accounts for phosphatide weight
When measuring percentage more than or equal to 5wt%, PFAT5 is gradually increased.(phosphatidylinositols accounts for phosphatide weight percent to comparative example 3
PFAT5 12wt%) is more than 0.05%.
The result of integration test example 1-3 is it can be found that when phosphatidylinositols accounts for the weight percent of phosphatide in model of the present invention
Available lysophosphatidyl choline content is lower when enclosing interior, and average grain diameter is stablized, the lower flurbiprofen axetil rouge of PFAT5
Fat cream.
Embodiment 7
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 65 DEG C, glycerol dissolution is added, as water phase；
(2) olive oil is taken, is heated to 65 DEG C, DSPC, DSPI and flurbiprofen axetil, stirring and dissolving, as oily phase is added；
(3) under high speed shear, oil is added in 65 DEG C of water phase, high speed shear speed 10000rpm, the time
10min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1000bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Embodiment 8
The component and dosage of flurbiprofen axetil Fat Emulsion, which are specifically shown in, see the table below.
Preparation method:
(1) water for injection is taken, is heated to 60 DEG C, glycerol dissolution is added, as water phase；
(2) olive oil and medium chain triglyceride are taken, is heated to 60 DEG C, phosphatidyl choline, the pure and mild fluorine ratio of phosphatidyl-4 is added
Ibuprofen ester, stirring and dissolving, as oily phase；
(3) under high speed shear, oil is added in 60 DEG C of water phase, high speed shear speed 8000rpm, time 10min,
Form colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1200bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Embodiment 9
The component and dosage of flurbiprofen axetil Fat Emulsion specifically see the table below.
Preparation method:
(1) water for injection is taken, is heated to 70 DEG C, glycerol dissolution is added, as water phase；
(2) soybean oil and medium chain triglyceride are taken, is heated to 70 DEG C, phosphatidyl choline, the pure and mild fluorine ratio of phosphatidyl-4 is added
Ibuprofen ester, stirring and dissolving, as oily phase；
(3) under high speed shear, oil is added in 70 DEG C of water phase, high speed shear speed 12000rpm, the time
15min forms colostrum；
(4) colostrum pH value is adjusted, is added to the full amount of water for injection；
(5) colostrum is transferred in high pressure homogenizer and is emulsified, homogenization pressure 1200bar, 3 circulations；
(6) it filters: by smart cream through 0.45 μm of filtering with microporous membrane, encapsulating；
(7) it sterilizes, encapsulating to obtain the final product.
Sample obtained by embodiment 7-9 through study on the stability the result shows that, average grain diameter is stablized, Flurbiprofen content compared with
Low, PFAT5 is respectively embodiment 7 (0.010%), embodiment 8 (0.013%), embodiment 9 (0.028%), and its haemolysis phosphorus
The content of phosphatidylcholine was below 1.0mg/ml at 60 DEG C 30 days.
The foregoing is only a preferred embodiment of the present invention, is not intended to restrict the invention, for the skill of this field
For art personnel, the invention may be variously modified and varied.All within the spirits and principles of the present invention, made any to repair
Change, equivalent replacement, improvement etc., should all be included in the protection scope of the present invention.
Claims (10)
1. a kind of flurbiprofen axetil Fat Emulsion, which is characterized in that containing the phosphatide containing phosphatidyl choline and phosphatidylinositols, wherein
The weight percent that the phosphatidylinositols accounts for the phosphatide is 1wt% ~ 10wt%.
2. flurbiprofen axetil Fat Emulsion according to claim 1, which is characterized in that the phosphatidylinositols accounts for the phosphatide
Weight percent be 1wt% ~ 8wt%.
3. flurbiprofen axetil Fat Emulsion according to claim 2, which is characterized in that the phosphatidylinositols accounts for the phosphatide
Weight percent be the wt% of 1 wt% ~ 5.
4. flurbiprofen axetil Fat Emulsion according to claim 3, which is characterized in that the phosphatidylinositols accounts for the phosphatide
Weight percent be greater than 1 wt% and less than 5 wt%；Preferably, the phosphatidylinositols accounts for the weight percent of the phosphatide
Than being greater than 1wt% and being less than or equal to 3wt%.
5. flurbiprofen axetil Fat Emulsion according to claim 1, which is characterized in that the phosphatidyl choline is selected from natural next
The phosphatidyl choline and its salt in source or one of the phosphatidyl choline of synthesis and its salt or a variety of；
Preferably, the natural phosphatidyl choline and its salt be the phosphatidyl choline extracted in soybean or yolk and its
Salt；
Preferably, the phosphatidyl choline and its salt of the synthesis include distearoyl phosphatidylcholine, dioleoyl phosphatidyl
Choline, Dioctonoyl pnosphotidyl choline, L-Dimyristoylphosphatidylcholine, Dinonyl Phosphatidylcholine DDPC, February
Osmanthus phosphatidyl choline, two mustard phosphatidyl cholines, 1- stearyl -2- oleolyl phosphatidyl choline, 1- palmityl -
2- oleolyl phosphatidyl choline, 1- myristoyl -2- oleolyl phosphatidyl choline, 1- stearyl -2- palmityl phosphatide
Phatidylcholine, 1- stearyl -2- myristoyl phosphatidyl choline, 1- palmityl -2- stearoyl phosphatidyl choline, 1- palm fibre
Palmitic acid acyl group -2- myristoyl phosphatidyl choline, 1- myristoyl -2- stearoyl phosphatidyl choline and 1- myristoyl
Base -2- palmityl phosphatidyl choline.
6. flurbiprofen axetil Fat Emulsion according to claim 1, which is characterized in that the phosphatidylinositols is selected from natural next
The phosphatidylinositols and its salt in source or one of the phosphatidylinositols of synthesis and its salt or a variety of；
Preferably, the natural phosphatidylinositols and its salt be the phosphatidylinositols extracted in soybean or yolk and its
Salt；
Preferably, the phosphatidylinositols and its salt of the synthesis include distearyl acyl group phosphatidylinositols, dioleoyl phosphatidyl
Inositol, two palmityl phosphatidylinositols, two myristoyl phosphatidylinositols, 1- palmityl -2- oleolyl phosphatidyl flesh
Alcohol, two pure and mild osmanthus in the February acyl phosphatidylinositols of mustard acyl phosphatidyl-4.
7. flurbiprofen axetil Fat Emulsion according to claim 1, which is characterized in that in the flurbiprofen axetil Fat Emulsion
Further include oil for injection, the oil for injection be selected from refined soybean oil, safflower oil, cottonseed oil, olive oil, coconut oil, castor oil,
Fish oil, medium chain mono, medium chain triglyceride dibasic acid esters, medium chain triglyceride, ethyl oleate, acetylated monoglyceride, propylene glycol are double
One of group of ester, glyceryl linoleate and polyethylene glycol glyceryl laurate ester composition is a variety of.
8. flurbiprofen axetil Fat Emulsion according to claim 1, which is characterized in that the flurbiprofen axetil Fat Emulsion also wraps
PH adjusting agent is included, the pH adjusting agent is selected from sodium hydroxide, hydrochloric acid, phosphoric acid, phosphate, citric acid, citrate, acetic acid and vinegar
One of group of hydrochlorate composition is a variety of.
9. flurbiprofen axetil Fat Emulsion according to claim 1, which is characterized in that the flurbiprofen axetil Fat Emulsion also wraps
Include isotonic regulator, the isotonic regulator be selected from one of group of glycerol, glucose, mannitol and propylene glycol composition or
It is a variety of.
10. a kind of preparation method of flurbiprofen axetil Fat Emulsion as claimed in any one of claims 1-9 wherein, which is characterized in that
The following steps are included:
1) preparation of oily phase: phosphatidyl choline, phosphatidylinositols, flurbiprofen axetil is added into oil for injection respectively, stirring makes
It is dissolved, as oily phase；
2) preparation of water phase: isotonic regulator is added in water for injection, and stirring obtains water phase to dissolving；
3) preparation of colostrum: oil made from step 1) is added in water phase made from step 2, and high speed shear dispersion is formed just
Cream；
4) high-pressure homogenising: regulating step 3) made from colostrum pH, it is high-pressure homogenising, obtain smart cream；
5) encapsulating sterilizes to get the flurbiprofen axetil Fat Emulsion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711482173.1A CN109985002A (en) | 2017-12-29 | 2017-12-29 | A kind of flurbiprofen axetil Fat Emulsion and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711482173.1A CN109985002A (en) | 2017-12-29 | 2017-12-29 | A kind of flurbiprofen axetil Fat Emulsion and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109985002A true CN109985002A (en) | 2019-07-09 |
Family
ID=67109828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711482173.1A Withdrawn CN109985002A (en) | 2017-12-29 | 2017-12-29 | A kind of flurbiprofen axetil Fat Emulsion and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109985002A (en) |
-
2017
- 2017-12-29 CN CN201711482173.1A patent/CN109985002A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240139201A1 (en) | Methods of use of emulsion formulations of aprepitant | |
| US12115255B2 (en) | Methods of use of emulsion formulations of an NK-1 receptor antagonist | |
| KR102027613B1 (en) | Hormone containing emulsion | |
| BR112012027279B1 (en) | low oil pharmaceutical emulsion compositions comprising progestogen | |
| JP6829257B2 (en) | Emulsion containing NK-1 receptor antagonist | |
| CN109715138A (en) | Prostacyclin analogs preparation | |
| US11779543B2 (en) | Ocular drug delivery | |
| JPH10510267A (en) | Emulsion suitable for administration of sphingolipid and use thereof | |
| CN109985005A (en) | Flurbiprofen axetil Fat Emulsion and preparation method thereof | |
| CN109985002A (en) | A kind of flurbiprofen axetil Fat Emulsion and preparation method thereof | |
| US20190231688A1 (en) | Method of administering emulsion formulations of an nk-1 receptor antagonist | |
| CN109985001A (en) | A kind of injection auxotype Fat Emulsion and preparation method thereof | |
| CN109985003A (en) | A kind of injection auxotype Fat Emulsion and preparation method thereof | |
| JP2021088583A (en) | Emulsion comprising nk-1 receptor antagonist | |
| CN104887628A (en) | Stable phenyl acetic acid ester medicinal fat emulsion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190709 |
|
| WW01 | Invention patent application withdrawn after publication |